NYSE:INO

Inovio Pharmaceuticals Stock Predictions

etoro logo Buy INO
*Your capital is at risk
$1.14
-0.0700 (-5.79%)
At Close: Jun 03, 2026
Currently predicting for Fri, 5 Jun 2026

INO Prediction Chart

INO Predictions History

Latest community submissions for INO.
Predictor Target Session Target Price Result Direction Accuracy Score
JS JS Pro
Feb 1, 2021 $12.27 -93.97% $16.96 V 72.35% 0
Shawn Coleman Shawn Coleman @ShawnColeman.193011
Feb 1, 2021 Bullish $16.96 X 1
JS JS Pro
Jan 27, 2021 $10.32 -93.12% $12.50 V 82.56% 0
אבי אבנר אבי אבנר @D790D791D799D790D791D7A0D7A8.191827
Jan 27, 2021 Bullish $12.50 X 1
JS JS Pro
Jan 22, 2021 $9.00 -91.67% $9.00 V 100.00% 10
Jan 22, 2021 Bearish $9.00 V 1
JS JS Pro
Jan 5, 2021 $9.84 -91.14% $9.26 X 93.74% 0
CORealtor CORealtor Merchant
Jan 5, 2021 $10.00 -91.00% $9.26 X 92.01% 0
JS JS Pro
Dec 28, 2020 $10.53 -90.86% $9.60 X 90.31% 0
Mark Mark Mark Mark @MarkMark.183012
Dec 28, 2020 $10.26 -91.09% $9.60 V 93.13% 1
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for INO with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT INOVIO PHARMACEUTICALS
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery o...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE